It was a pleasure to meet with Professor Robert Terkeltaub (UC San Diego, San Diego, California, USA) to discuss the efficacy and safety findings from the phase 2 study of tigulixostat in gout with hyperuricemia (NCT03934099).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia.‘ (Abstract number: L05) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- What are the limitations of current treatment options for gout? (0:12)
- Could you tell us a little about tigulixostat and its potential advantages over febuxostat? (1:00)
- What were the aims and methodology of your Phase II study investigating tigulixostat? (2:16)
- What were the efficacy and safety findings with the different dose levels? (3:51)
- What will be the next step in the clinical development of tigulixostat? (5:39)
Disclosures: Robert Terkeltaub discloses research grants from Astra-Zeneca and consulting for LG, Allena, Dyve, Fortress Bio, Astra-Zeneca.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
